IHC LYMPHOMA PANEL

The IHC Lymphoma Panel is an advanced immunohistochemistry (IHC) diagnostic test panel used to identify and classify lymphoid cancers, including Hodgkin lymphoma and non-Hodgkin lymphoma. This comprehensive panel evaluates multiple tissue markers that help pathologists accurately determine the type, subtype, and biological characteristics of lymphoma cells.

Lymphoma develops when abnormal lymphocytes, a type of white blood cell, grow uncontrollably within lymph nodes, bone marrow, or other tissues. Since many lymphoma subtypes have similar microscopic appearances, immunohistochemistry is essential for distinguishing one subtype from another and guiding appropriate treatment.

The IHC Lymphoma Panel uses carefully selected biomarkers such as CD20, CD3, CD5, CD10, CD15, CD30, BCL2, BCL6, Ki-67, Cyclin D1, CD23, and other relevant markers, depending on the clinical case. These markers help identify whether the lymphoma originates from B-cells, T-cells, or other lymphoid cells.

Benefits of the Test

The IHC Lymphoma Panel offers several important clinical benefits:

• Helps accurately diagnose lymphoma
• Classifies lymphoma subtype precisely
• Differentiates Hodgkin and non-Hodgkin lymphoma
• Assists in determining disease aggressiveness
• Supports prognosis assessment
• Helps guide personalized treatment planning

This test is critical for selecting the most effective therapy.

Why Doctors Recommend This Test

Doctors recommend the IHC Lymphoma Panel when lymphoma is suspected or when detailed tissue classification is required.

It is commonly advised for:

• Enlarged lymph node evaluation
• Suspected lymphoma diagnosis
• Confirmation of lymphoid malignancy
• Subtyping Hodgkin or non-Hodgkin lymphoma
• Oncology treatment planning and prognosis evaluation

The results help hematologists and oncologists choose targeted and effective therapies.

Preparation Before Test

No special preparation is required from the patient. The test is performed on lymph node biopsy or tissue specimens collected during routine diagnostic procedures.

Normal Reporting Time

The usual turnaround time for the IHC Lymphoma Panel is 5 to 10 working days, depending on marker complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients with enlarged lymph nodes
• Individuals suspected of lymphoma
• Patients requiring lymphoma subtype classification
• Cases needing advanced tissue diagnosis
• Oncology patients requiring treatment planning

The IHC Lymphoma Panel is a vital diagnostic tool in hematopathology. It provides accurate lymphoma classification, supports early diagnosis, and helps clinicians create personalized treatment strategies for better patient outcomes.